Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Gynecology | Oncology | Pathology | Journal

Back to Journal Articles

Mutant Tumor Suppressor Gene ID’d in Mucinous Ovarian Tumors

Last Updated: November 01, 2012.

 

RNF43 ranked second in mutational frequency to KRAS; similar to BRAF, TP53

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
The mutated tumor suppressor gene RNF43 is involved in mucinous ovarian tumors, according to a study published online Oct. 24 in The Journal of Pathology.

THURSDAY, Nov. 1 (HealthDay News) -- The mutated tumor suppressor gene RNF43 is involved in mucinous ovarian tumors, according to a study published online Oct. 24 in The Journal of Pathology.

Georgina L. Ryland, from the Peter MacCallum Cancer Centre in East Melbourne, Australia, and colleagues performed whole exome sequencing on 12 primary mucinous tumors of the ovary to examine the genetic basis of mucinous tumor development.

The researchers found that one of the most frequently somatically mutated genes was RNF43, which was secondary to KRAS, and mutated at the same frequency as TP53 and BRAF. In a larger cohort of ovarian tumors, further screening identified additional mutations, with a total frequency of 9 percent in mucinous ovarian borderline tumors and 21 percent in mucinous ovarian carcinomas. In silico analysis predicted that seven mutations would truncate the protein and one missense mutation would be deleterious. Allelic imbalance with loss of the wild type allele at the RNF43 locus was noted in six tumors.

"In summary, our findings strongly implicate RNF43 as a candidate tumor suppressor gene in ovarian tumors of mucinous histology and raise the possibility that other genetic similarities exist between ovarian and non-ovarian mucinous tumors," the authors write.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Differential miRNA Expression IDs Urothelial Cancer Grade Next: Alemtuzumab Reduces Relapses in Relapsing-Remitting MS

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.